VANCOUVER, May 15, 2019 /CNW/ - Sirona Biochem Corp. (TSXV:
SBM) (FSE: ZSB) ("Sirona") is pleased to announce results of
a clinical trial performed in the Peoples
Republic of China (China)
using Sirona's novel skin lightening agent TFC-1067. Sirona's
TFC-1067 once again demonstrated significant clinical lightening
effect without any reported adverse effects.
A major distributor of cosmetics materials in China arranged clinical testing of TFC-1067 to
be done by a select group of its key cosmetic customers. The
formulation used in the studies was the same as that used in
Sirona's first clinical trial in the USA by Dr. Zoe
Draelos. The clinical trial design protocols and the testing
was conducted independently of Sirona by the cosmetic companies.
The studies were conducted in Guangzhou,
China.
A total of 60 participants were involved in the studies
conducted over several sites. All participants applied the
formulation with TFC-1067 twice daily to the face. Each study
duration was 4 weeks. During the 4 weeks 90% of participant
reported a brightening effect with TFC-1067. Sirona is informed by
the distributor that a second set of trials with Sirona's improved,
next generation, formulation is underway.
Dr. Géraldine Deliencourt-Godefroy, Chief Scientific Officer of
Sirona Biochem stated, "These are excellent clinical results. Based
on the outcome from our first clinical trial, we are pleased to see
such results for the short 4-week duration of the testing. This
positive testing result on Asian skin with the observed lightening
effect supports the clinical effect of TFC-1067 over different skin
types. A longer trial is required to assess dyschromia which was
assessed in Sirona's US based clinical trial. Sirona will await
feedback on the further testing currently ongoing in China with our new formulation."
"No clinical safety issues were reported with TFC-1067 during
the trial. TFC-1067 has shown a lightening effect over a short
clinical trial on Asian skin types." reports Dr. Howard Verrico, CEO of Sirona Biochem. "Although
we prefer to conduct trials with a double blinded protocol using a
comparative compound and a longer trial duration as we arranged in
the USA, it was important to have
these cosmetic companies perform their own clinical testing
independently and be confident of the results. TFC-1067 continues
to deliver excellent clinical results as anticipated by our
preclinical assays. A strong commercial interest in TFC-1067 is
already reported by the distributor based on current results."
"Sirona's team remains dedicated to work towards entering this
market with a safe and effective alternative to current options. We
are moving forward on building our relationship with the Chinese
distributor with more positive news anticipated near term", Dr.
Verrico concluded.
The global skin lightening market is estimated to grow to
US$31.2 billion by 20241.
Asia makes up the largest and
fastest growing segment of the market. A World Health
Organization survey reported that nearly 40 per cent of women
polled in China said they
regularly used whitening products many of which are
toxic2.
______________________________
1 https://www.factmr.com/report/309/skin-lightening-products-market
2 http://theglobalfool.com/tag/mercury/
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French
national scientific awards and European Union and French government
grants. For more information, please
visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this press release.
_________________________
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.